Figures computed from official regulatory filings — .
Analysttarget 27 USD (+247%) · consensus 3.7/5 · 4 buy · 6 hold · 0 sell
Ownershipinsiders 9.44% · institutions 76.47% · short 37.4% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for CAPRICOR THERAPEUTICS, INC. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
73 buys37 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Baker Bros. Advisors (GP) LLCtrack record | Other | n/a (No price was disclosed in the filing) | SEC |
| Baker Bros. Advisors (GP) LLCtrack record | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Baker Bros. Advisors (GP) LLCtrack record | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Baker Bros. Advisors (GP) LLCtrack record | Other | n/a (No price was disclosed in the filing) | SEC |
| Baker Brothers Life Sciences LPtrack record | Buy | $3.5K | conv 17 | SEC |
| Baker Brothers Life Sciences LPtrack record | Buy | $3K | conv 17 | SEC |
| Baker Brothers Life Sciences LPtrack record | Buy | $11.6K | conv 18 | SEC |
| Baker Brothers Life Sciences LPtrack record | Buy | $141.2K | conv 18 | SEC |
| Baker Brothers Life Sciences LPtrack record | Buy | $5.3K | conv 18 | SEC |
| Baker Brothers Life Sciences LPtrack record | Buy | $90.4K | conv 37First in 12mo | SEC |
| Baker Brothers Life Sciences LPtrack record | Buy | $239.9 | conv 24First in 12mo | SEC |
| Baker Brothers Life Sciences LPtrack record | Buy | $64.2K | conv 18 | SEC |
| Baker Brothers Life Sciences LPtrack record | Buy | $42.2K | conv 17 | SEC |
| Baker Brothers Life Sciences LPtrack record | Buy | $2.9K | conv 24First in 12mo | SEC |
| Baker Brothers Life Sciences LPtrack record | Buy | $248.9 | conv 17 | SEC |
| Baker Brothers Life Sciences LPtrack record | Buy | $1.1M | conv 38First in 12mo | SEC |
| Smith Sean Michael | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Smith Sean Michael | Sell | $820.3 | SEC |
| Smith Sean Michael | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Baker Brothers Life Sciences LPtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Baker Brothers Life Sciences LPtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SIMPSON TODD E | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Noonberg Sarah B. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Babler Martin | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| PALEKAR ROHAN | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |